Hyperhaploidy is a novel high-risk cytogenetic subgroup in multiple myeloma

被引:26
作者
Sawyer, J. R. [1 ,2 ]
Tian, E. [2 ]
Shaughnessy, J. D., Jr. [3 ]
Epstein, J. [2 ]
Swanson, C. M. [1 ]
Stangeby, C. [1 ]
Hale, C. L. [1 ]
Parr, L. [1 ]
Lynn, M. [1 ]
Sammartino, G. [1 ]
Lukacs, J. L. [1 ]
Stein, C. [2 ]
Bailey, C. [2 ]
Zangari, M. [2 ]
Davies, F. E. [2 ]
Van Rhee, F. [2 ]
Barlogie, B. [2 ]
Morgan, G. J. [2 ]
机构
[1] Univ Arkansas Med Sci, Dept Pathol, Little Rock, AR 72205 USA
[2] Univ Arkansas Med Sci, Myeloma Inst, Little Rock, AR 72205 USA
[3] Signal Genet Inc, Carlsbad, CA USA
关键词
ACUTE LYMPHOBLASTIC-LEUKEMIA; IN-SITU HYBRIDIZATION; PERICENTROMERIC HETEROCHROMATIN; MOLECULAR CLASSIFICATION; JUMPING TRANSLOCATIONS; CHROMOSOME-ABERRATIONS; PROGNOSTIC VALUE; STRATIFICATION; MECHANISM; IMPACT;
D O I
10.1038/leu.2016.253
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Hyperhaploid clones (24-34 chromosomes) were identified in 33 patients with multiple myeloma (MM), demonstrating a novel numerical cytogenetic subgroup. Strikingly, all hyperhaploid karyotypes were found to harbor monosomy 17p, the single most important risk stratification lesion in MM. A catastrophic loss of nearly a haploid set of chromosomes results in disomies of chromosomes 3, 5, 7, 9, 11, 15, 18, 19 and 21, the same basic set of odd-numbered chromosomes found in trisomy in hyperdiploid myeloma. All other autosomes are found in monosomy, resulting in additional clinically relevant monosomies of 1p, 6q, 13q and 16q. Hypotriploid subclones (58-68 chromosomes) were also identified in 11 of the 33 patients and represent a duplication of the hyperhaploid clone. Analysis of clones utilizing interphase fluorescence in situ hybridization (iFISH), metaphase FISH and spectral karyotyping identified either monosomy 17 or del17p in all patients. Amplification of 1q21 was identified in eight patients, demonstrating an additional high-risk marker. Importantly, our findings indicate that current iFISH strategies may be uninformative or ambiguous in the detection of these clones, suggesting this patient subgroup maybe underreported. Overall survival for patients with hyperhaploid clones was poor, with a 5-year survival rate of 23.1%. These findings identify a distinct numerical subgroup with cytogenetically defined high-risk disease.
引用
收藏
页码:637 / 644
页数:8
相关论文
共 44 条
[1]   The Impact of Clone Size on the Prognostic Value of Chromosome Aberrations by Fluorescence In Situ Hybridization in Multiple Myeloma [J].
An, Gang ;
Li, Zengjun ;
Tai, Yu-Tzu ;
Acharya, Chirag ;
Li, Qian ;
Qin, Xiaoqi ;
Yi, Shuhua ;
Xu, Yan ;
Feng, Xiaoyan ;
Li, Chengwen ;
Zhao, Jiawei ;
Shi, Lihui ;
Zang, Meirong ;
Deng, Shuhui ;
Sui, Weiwei ;
Hao, Mu ;
Zou, Dehui ;
Zhao, Yaozhong ;
Qi, Junyuan ;
Cheng, Tao ;
Ru, Kun ;
Wang, Jianxiang ;
Anderson, Kenneth C. ;
Qiu, Lugui .
CLINICAL CANCER RESEARCH, 2015, 21 (09) :2148-2156
[2]   Combining fluorescent in situ hybridization data with ISS staging improves risk assessment in myeloma: an International Myeloma Working Group collaborative project [J].
Avet-Loiseau, H. ;
Durie, B. G. M. ;
Cavo, M. ;
Attal, M. ;
Gutierrez, N. ;
Haessler, J. ;
Goldschmidt, H. ;
Hajek, R. ;
Lee, J. H. ;
Sezer, O. ;
Barlogie, B. ;
Crowley, J. ;
Fonseca, R. ;
Testoni, N. ;
Ross, F. ;
Rajkumar, S. V. ;
Sonneveld, P. ;
Lahuerta, J. ;
Moreau, P. ;
Morgan, G. .
LEUKEMIA, 2013, 27 (03) :711-717
[3]   Impact of high-risk cytogenetics and prior therapy on outcomes in patients with advanced relapsed or refractory multiple myeloma treated with lenalidomide plus dexamethasone [J].
Avet-Loiseau, H. ;
Soulier, J. ;
Fermand, J-P ;
Yakoub-Agha, I. ;
Attal, M. ;
Hulin, C. ;
Garderet, L. ;
Belhadj, K. ;
Dorvaux, V. ;
Minvielle, S. ;
Moreau, P. .
LEUKEMIA, 2010, 24 (03) :623-628
[4]   Long-Term Analysis of the IFM 99 Trials for Myeloma: Cytogenetic Abnormalities [t(4;14), del(17p), 1q gains] Play a Major Role in Defining Long-Term Survival [J].
Avet-Loiseau, Herve ;
Attal, Michel ;
Campion, Loic ;
Caillot, Denis ;
Hulin, Cyrille ;
Marit, Gerald ;
Stoppa, Anne-Marie ;
Voillat, Laurent ;
Wetterwald, Marc ;
Pegourie, Brigitte ;
Voog, Eric ;
Tiab, Mourad ;
Banos, Anne ;
Jaubert, Jerome ;
Bouscary, Didier ;
Macro, Margaret ;
Kolb, Brigitte ;
Traulle, Catherine ;
Mathiot, Claire ;
Magrangeas, Florence ;
Minvielle, Stephane ;
Facon, Thierry ;
Moreau, Philippe .
JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (16) :1949-1952
[5]   Prognostic Significance of Copy-Number Alterations in Multiple Myeloma [J].
Avet-Loiseau, Herve ;
Li, Cheng ;
Magrangeas, Florence ;
Gouraud, Wilfried ;
Charbonnel, Catherine ;
Harousseau, Jean-Luc ;
Attal, Michel ;
Marit, Gerald ;
Mathiot, Claire ;
Facon, Thierry ;
Moreau, Philippe ;
Anderson, Kenneth C. ;
Campion, Loic ;
Munshi, Nikhil C. ;
Minvielle, Stephane .
JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (27) :4585-4590
[6]   Incorporating bortezomib into upfront treatment for multiple myeloma: early results of total therapy 3 [J].
Barlogie, Bart ;
Anaissie, Elias ;
van Rhee, Frits ;
Haessler, Jeffrey ;
Hollmig, Klaus ;
Pineda-Roman, Mauricio ;
Cottler-Fox, Michele ;
Mohiuddin, Abid ;
Alsayed, Yazan ;
Tricot, Guido ;
Bolejack, Vanessa ;
Zangari, Maurizio ;
Epstein, Joshua ;
Petty, Nathan ;
Steward, Douglas ;
Jenkins, Bonnie ;
Gurley, Jennifer ;
Sullivan, Ellen ;
Crowley, John ;
Shaughnessy, John D. Jr .
BRITISH JOURNAL OF HAEMATOLOGY, 2007, 138 (02) :176-185
[7]   Curing myeloma at last: defining criteria and providing the evidence [J].
Barlogie, Bart ;
Mitchell, Alan ;
van Rhee, Frits ;
Epstein, Joshua ;
Morgan, Gareth J. ;
Crowley, John .
BLOOD, 2014, 124 (20) :3043-3051
[8]   Molecular classification and risk stratification of myeloma [J].
Bergsagel, P. Leif ;
Chesi, Marta .
HEMATOLOGICAL ONCOLOGY, 2013, 31 :38-41
[9]   A novel prognostic model in myeloma based on co-segregating adverse FISH lesions and the ISS: analysis of patients treated in the MRC Myeloma IX trial [J].
Boyd, K. D. ;
Ross, F. M. ;
Chiecchio, L. ;
Dagrada, G. P. ;
Konn, Z. J. ;
Tapper, W. J. ;
Walker, B. A. ;
Wardell, C. P. ;
Gregory, W. M. ;
Szubert, A. J. ;
Bell, S. E. ;
Child, J. A. ;
Jackson, G. H. ;
Davies, F. E. ;
Morgan, G. J. .
LEUKEMIA, 2012, 26 (02) :349-355
[10]   Mapping of Chromosome 1p Deletions in Myeloma Identifies FAM46C at 1p12 and CDKN2C at 1p32.3 as Being Genes in Regions Associated with Adverse Survival [J].
Boyd, Kevin D. ;
Ross, Fiona M. ;
Walker, Brian A. ;
Wardell, Christopher P. ;
Tapper, William J. ;
Chiecchio, Laura ;
Dagrada, GianPaolo ;
Konn, Zoe J. ;
Gregory, Walter M. ;
Jackson, Graham H. ;
Child, J. Anthony ;
Davies, Faith E. ;
Morgan, Gareth J. .
CLINICAL CANCER RESEARCH, 2011, 17 (24) :7776-7784